Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Viral Genetics’ HIV drug confirms antiviral activity
Specifically, the results indicate that a proportion of patients receiving eight weeks of treatment with VGV-1 and no additional anti-HIV therapy experienced a decrease in viral load at
Specifically, the results indicate that a proportion of patients receiving eight weeks of treatment with VGV-1 and no additional anti-HIV therapy experienced a decrease in viral load at
The first study, placebo-controlled dose- ranging study, examined 146 acutely decompensated heart failure (ADHF) patients with kidney dysfunction. The preliminary data suggest KW-3902 has significant diuretic activity over
The data, presented at the European Hematology Association meeting in Amsterdam, looked retrospectively at 15 patients with chronic or accelerated phase chronic myeloid leukemia (CML) who had received
Ista has invested approximately $8 million for each of the drug candidates which, if approved, will be complementary to Istalol, Ista’s once-daily beta blocker marketed for the treatment
The company received a special protocol assessment letter from the FDA indicating that the trial design is sufficient to support eventual approval of the drug. The trial is
The data, presented by Merck/Schering-Plough at the International Symposium on Atherosclerosis meeting in Rome, show that Vytorin was more effective than Crestor across all study dose comparisons, 52-61%
Biotechnology company Amgen presented the data at the European Society of Cardiology-Heart Failure Congress. Approximately 20 to 30% of people diagnosed with heart failure also suffer from anemia,
Data from this study demonstrated that treatment with eltrombopag resulted in a significant increase in platelet count compared to placebo across a variety of typically poorly responding idiopathic
The trial is specifically evaluating the safety and tolerability of a continuous infusion of MT103 over a 4- to 8-week period at escalating dose levels. The data were
According to the company, these two disease conditions may represent a continuum in malignant progression of the abnormal production of blood cells in the bone marrow that results